Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 1993;13:1346-1349

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davi, G.
Right arrow Articles by Notarbartolo, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davi, G.
Right arrow Articles by Notarbartolo, A.

Arteriosclerosis and Thrombosis, Vol 13, 1346-1349, Copyright © 1993 by American Heart Association

ARTICLES

Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus

G Davi, C Patrono, I Catalano, N Custro, C Giammarresi, A Ganci, F Cosentino and A Notarbartolo
Department of Pharmacology, University of Chieti School of Medicine, Italy.

Indobufen is a reversible inhibitor of platelet prostaglandin G/H- synthase. To verify the dose dependence of the antiplatelet effect of indobufen on ex vivo and in vivo indexes of thromboxane (TX) biosynthesis and TXA2-dependent platelet function, we studied nine patients with non-insulin-dependent diabetes mellitus (NIDDM). This was a randomized, double-blind, crossover study in which each patient was treated with three different daily regimens (50 mg BID, 100 mg BID, and 200 mg BID) of indobufen for 1 week, with a 7-day washout period between treatments. Urinary 11-dehydro-TXB2 excretion averaged 58.2 +/- 21.8 ng/h at baseline. TX metabolite excretion was reduced dose dependently by indobufen: by 67% at 50 mg BID, 72% at 100 mg BID, and 81% at 200 mg BID. Platelet cyclooxygenase activity, ATP release, collagen-induced platelet aggregation, and bleeding time also were modified dose dependently by indobufen. Biochemical demonstration of suppressed platelet TXA2 in vivo was accompanied by evidence of inhibited platelet function as assessed ex vivo. Under pathophysiological conditions, such as NIDDM, which are associated with enhanced TXA2 synthesis, more than 95% suppression of platelet cyclooxygenase activity may be necessary to produce virtually maximal inhibition of platelet TXA2 biosynthesis in vivo.


This article has been cited by other articles:


Home page
 ChestHome page
C. Patrono, C. Baigent, J. Hirsh, and G. Roth
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 199S - 233S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 234S - 264S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth
Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects
Chest, January 1, 2001; 119 (2009): 39S - 63S.
[Full Text] [PDF]

Home page
 Cardiovasc ResHome page
P. Arvola, X. Wu, M. Kahonen, H. Makynen, A. Riutta, I. Mucha, T. Solakivi, H. Kainulainen, and I. Porsti
Exercise enhances vasorelaxation in experimental obesity associated hypertension
Cardiovasc Res, September 1, 1999; 43(4): 992 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
F. Cipollone, P. Patrignani, A. Greco, M. R. Panara, R. Padovano, F. Cuccurullo, C. Patrono, A. G. Rebuzzi, G. Liuzzo, G. Quaranta, et al.
Differential Suppression of Thromboxane Biosynthesis by Indobufen and Aspirin in Patients With Unstable Angina
Circulation, August 19, 1997; 96(4): 1109 - 1116.
[Abstract] [Full Text]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1993 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.